Idexx Laboratories Inc  (IDXX)
Other Ticker:  
Price: $521.5600 $2.61 0.503%
Day's High: $529.56 Week Perf: 11.97 %
Day's Low: $ 516.63 30 Day Perf: 23.29 %
Volume (M): 682 52 Wk High: $ 564.74
Volume (M$): $ 355,652 52 Wk Avg: $473.18
Open: $521.19 52 Wk Low: $372.50

 Market Capitalization (Millions $) 43,807
 Shares Outstanding (Millions) 84
 Employees 10,350
 Revenues (TTM) (Millions $) 3,587
 Net Income (TTM) (Millions $) 823
 Cash Flow (TTM) (Millions $) 233
 Capital Exp. (TTM) (Millions $) 150

Idexx Laboratories Inc
IDEXX Laboratories Inc.
is a global company that provides diagnostics, software, and solutions for the veterinary, livestock, and poultry industries.
It was founded in 1983 and is headquartered in Westbrook, Maine, United States.
The company develops and manufactures a wide range of products, including diagnostic tests, point-of-care analyzers, imaging systems, and software solutions, which help veterinarians diagnose, treat, and manage diseases in animals.
IDEXX has an extensive product portfolio, which includes tests for detecting infectious diseases such as parvovirus, Lyme disease, and feline leukemia, as well as tests for monitoring organ and blood functions in animals.
Its point-of-care analyzers, such as the IDEXX VetLab Station and IDEXX SNAP Pro Analyzer, provide fast and accurate results, enabling veterinarians to make quick and informed decisions regarding animal care.
Moreover, IDEXX Laboratories Inc.
provides software solutions that help veterinary practices manage their operations, billing, and patient records.
IDEXX Neo is a cloud-based practice management software that streamlines workflow, improves communication with clients, and enhances patient care.
IDEXX Laboratories Inc.
operates in more than 175 countries and has over 9,000 employees worldwide.
It generates over $2 billion in revenue annually and has consistently been ranked as one of the best places to work in the United States.
The company's commitment to research and development has resulted in many innovative products and solutions, making it a leader in animal healthcare.

   Company Address: One IDEXX Drive Westbrook 4092 ME
   Company Phone Number: 556-0300   Stock Exchange / Ticker: NASDAQ IDXX
   IDXX is expected to report next financial results on February 15, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Mymd Pharmaceuticals Inc

Mymd Pharmaceuticals Inc's Troubling Third Quarter Earnings: A Bumpy Ride for Investors

During the past week, Mymd Pharmaceuticals Inc experienced a significant decline in its shares, dropping by -7.89%. This downward movement has further contributed to the company's already poor year-to-date performance, which now stands at -76.07%. Additionally, Mymd Pharmaceuticals Inc shares are currently trading only 7.6% above their 52-week low.
This decline in share value comes at a time when the In Vitro and In Vivo Diagnostic Substances industry is evaluating the third-quarter earnings of 2023. Specifically, MYMD, a key contributor to this industry, reported an operating loss of $-3.842588 million for the period between July and September 30, 2023. It is important to note that MYMD has not yet generated any revenue during this reporting season. However, market analysts anticipate additional revenue sources to emerge soon, given the current stage of the entity.

Oncocyte Corporation

Oncocyte Corporation's Revenue Surges in Q3 2023, but Profitability Remains Elusive

Oncocyte Corporation, a leading player in the In Vitro and In Vivo Diagnostic Substances industry, recently released its financial results for the third quarter of 2023. Despite reporting a significant increase in revenue compared to the same period last year, the company witnessed a widening of its losses. This article will outline the key facts from Oncocyte Corporation's financial results and provide context to better understand the company's performance in the industry.
Revenue Growth and Comparisons:
Oncocyte Corporation announced an impressive year-on-year revenue advancement of 946.341% in the third quarter of 2023, reaching $0.43 million. This growth significantly outperformed its industry peers, who reported an aggregated 11.10% top-line advance during the same period. However, it is important to note that the company's revenue deteriorated by -7.343% from the previous reporting season, where it recorded $0.46 million in revenue.

Volitionrx Limited

Volitionrx Limited's Stock Skyrockets, but Challenges Loom: A Closer Look at the Company's Financial Results and Future Prospects

Volitionrx Limited, a biomedical company that specializes in blood-based diagnostics, experienced a significant increase in its stock value over the past week and month. However, despite robust revenue growth, the company continues to face challenges. This article delves into Volitionrx Limited's recent financial results and analyzes how these factors may impact the company's future prospects.
Impressive Revenue Growth:
Volitionrx Limited reported a remarkable year-on-year revenue increase of 405.016% to $0.17 million in the most recent fiscal period. This surge indicates a strong demand for the company's blood-based diagnostic solutions. Such exponential revenue growth demonstrates a positive market reception of Volitionrx's products and services.

Navidea Biopharmaceuticals Inc

Navidea Biopharmaceuticals Inc Turns the Tide: Destroys Deficit with $0.02 Per Share Profit in Q3 2023!

Navidea Biopharmaceuticals Inc (NAVB) has recently reported its financial results for the fiscal time-frame of July to September 2023. While the company did incur losses of $-0.02 per share during this period, it is worth noting the significant improvement compared to a loss of $-0.25 per share in the same quarter last year. Furthermore, earnings per share fell from $0.12 per share in the previous quarter, indicating a slight setback.
Although the revenue remained stagnant at $0.00 million, it is important to recognize that this figure was also consistent with the previous year's comparable quarter. Additionally, the revenue remained unchanged sequentially, indicating stability in the company's financial performance.

Aspira Women S Health Inc

Aspira Women S Health Inc registers steady top-line growth in their recent fiscal period

Aspira Women's Health Inc, a leading healthcare company focused on women's health, recently released its financial results for the third quarter of 2023. The company reported a significant increase in the shortfall per share compared to the same period last year and the preceding reporting season. For the financial third quarter of 2023, AWH recorded a shortfall of $-0.48 per share, which is higher than the $-0.04 per share reported a year ago and the $-0.28 per share from the preceding reporting season.
In terms of revenue, Aspira Women's Health Inc experienced growth in comparison to the same reporting season a year ago, with a 6.998% increase, reaching $2.22 million from $2.07 million. However, the sequential revenue showed a deterioration of -11%, falling from $2.49 million in the previous reporting season.


Idexx Laboratories Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com